Compass Therapeutics (CMPX) Common Equity (2023 - 2025)
Historic Common Equity for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to $209.6 million.
- Compass Therapeutics' Common Equity rose 5145.67% to $209.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $209.6 million, marking a year-over-year increase of 5145.67%. This contributed to the annual value of $125.2 million for FY2024, which is 1568.96% down from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Common Equity is $209.6 million, which was up 5145.67% from $93.2 million recorded in Q2 2025.
- Compass Therapeutics' 5-year Common Equity high stood at $209.6 million for Q3 2025, and its period low was $93.2 million during Q2 2025.
- For the 3-year period, Compass Therapeutics' Common Equity averaged around $148.4 million, with its median value being $148.5 million (2023).
- Over the last 5 years, Compass Therapeutics' Common Equity had its largest YoY gain of 5145.67% in 2025, and its largest YoY loss of 3620.5% in 2025.
- Compass Therapeutics' Common Equity (Quarter) stood at $148.5 million in 2023, then dropped by 15.69% to $125.2 million in 2024, then soared by 67.38% to $209.6 million in 2025.
- Its Common Equity stands at $209.6 million for Q3 2025, versus $93.2 million for Q2 2025 and $110.3 million for Q1 2025.